Member Info for Laura2022

How do u know

1) you weren't at the presentation or you would have said

2) it's not on the website yet

3) you AREN'T a shareholder

4) u do U turns every month

Defiant

I stopped clock is right once

The webinar will be available to view on demand through our website after the event.

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.

Should be this week after 2 weeks of churning and very oversold

Will be on website today i assume for all to watch /judge

Strange that porky STILL hasn't found time to post on his beloved GDR which had a strange RNS yesterday

Morning GB

It's simple...if a deal for VAL gets done it's staged payments up to $30mln for VAL and up to £6mln to PYC

The new CEO posted from day 1 that he's alliigned and committed via RNS and LinkedIn on day of appointment

He's also a shareholder

Pj

Totally agree and his email to me back in summer was indicative of this new focus

He hates directors failings and high wages yet GDR CEO earns £250k+ and presides over a £5mln loss making per year company and where one director today has shown he's clearly not fit to be part of a listed.company

Yet...Porky has posted 13 times here and 0 on GDR

He needs medical help

Youve got it wrong PM

GDR is going to £250mln/50p according to Porky

Still no posts on the highly dubious GDR RNS porky

Yet 10+ here

You naughty piglet

Supporting the development and evaluation of new treatments for rare diseases is a key priority for the FDA. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including:

Tax credits for qualified clinical trials

Exemption from user fees

Potential seven years of market exclusivity after approval

Sponsors seeking orphan drug designation for a drug must submit a request for designation to the agency. Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated product must submit their own data and information to support their designation request. Orphan drug designation is a separate process from seeking approval or licensing. Drugs for rare diseases go through the same rigorous scientific review process as any other drug for approval or licensing.

Maybe read the last few RNS, listen to the Sept Q and A and this one once released THEN make judgement

He's an utter pain

I filtered him months ago

Quick look at his drivel over last 12mths tells us all

LWHL

The CEO even stated what the purpose of today's meeting was for

Namely to "outline the future direction "

The new CEO has already made his mark this last 3mths after 2yrs woeful mgmt

Very strange 1st post on VAL ?

Out of all the shares on AIM that has a rise you chose here

There was an investor presentation which was public at 1pm and anyone could choose to listen in....clearly 100s liked what they heard

It's being made available on VAL website shortly

Uncanny

It's the U turns and the fact they can happen with very little different information

From 29th Sept...he then changed this bullish stance just a week or so later

Uncanny

Posted in: VAL

Posts: 2,770

Price: 1.45

No Opinion

RE: Granger34529 Sep 2024 09:39

201 - ME has served an ultimatum on THX so its fight or flight, so if flight will be offered to other interested parties so will be licensed at some point IMHO OR we may all be struck down in disbelief and THX perform!

401 -Ambrose have nearly raised the funds and we are informed from their website that they like the product so we will hear in the next 3 months.

CLX - this l am hoping will be licensed early and very exciting at the results thus far.